Zacks Research Issues Pessimistic Forecast for MMSI Earnings

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Equities research analysts at Zacks Research dropped their Q2 2025 earnings estimates for Merit Medical Systems in a research report issued on Thursday, May 15th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will post earnings per share of $0.87 for the quarter, down from their previous estimate of $0.96. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.37 per share. Zacks Research also issued estimates for Merit Medical Systems’ Q3 2025 earnings at $0.81 EPS, FY2025 earnings at $3.39 EPS, Q2 2026 earnings at $0.97 EPS, FY2026 earnings at $3.77 EPS, Q1 2027 earnings at $0.92 EPS and FY2027 earnings at $4.12 EPS.

Merit Medical Systems (NASDAQ:MMSI) last announced its quarterly earnings results on Thursday, April 24th. The medical instruments supplier reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.75 by $0.11. Merit Medical Systems had a net margin of 9.05% and a return on equity of 15.61%. The business had revenue of $355.35 million during the quarter, compared to the consensus estimate of $352.57 million. During the same quarter last year, the firm earned $0.77 EPS. The business’s revenue was up 9.8% compared to the same quarter last year.

MMSI has been the subject of a number of other reports. Piper Sandler cut their price objective on Merit Medical Systems from $116.00 to $112.00 and set an “overweight” rating for the company in a research report on Wednesday, April 23rd. JPMorgan Chase & Co. initiated coverage on shares of Merit Medical Systems in a research report on Friday, March 28th. They set an “overweight” rating and a $120.00 price target for the company. Barrington Research decreased their price objective on shares of Merit Medical Systems from $111.00 to $103.00 and set an “outperform” rating on the stock in a report on Friday, April 25th. Wells Fargo & Company set a $106.00 price objective on shares of Merit Medical Systems and gave the stock an “overweight” rating in a research report on Friday, April 25th. Finally, Robert W. Baird cut their target price on Merit Medical Systems from $111.00 to $110.00 and set an “outperform” rating on the stock in a research report on Friday, April 25th. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $108.67.

Merit Medical Systems Price Performance

MMSI stock opened at $97.57 on Friday. Merit Medical Systems has a 52-week low of $80.02 and a 52-week high of $111.45. The company has a quick ratio of 3.82, a current ratio of 5.36 and a debt-to-equity ratio of 0.57. The stock has a market cap of $5.77 billion, a price-to-earnings ratio of 47.83, a price-to-earnings-growth ratio of 2.34 and a beta of 0.70. The business has a fifty day moving average of $96.74 and a two-hundred day moving average of $100.53.

Insiders Place Their Bets

In other news, CEO Fred P. Lampropoulos sold 31,320 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $103.86, for a total transaction of $3,252,895.20. Following the sale, the chief executive officer now owns 1,086,028 shares of the company’s stock, valued at approximately $112,794,868.08. This trade represents a 2.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Brian G. Lloyd sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $99.50, for a total transaction of $2,487,500.00. Following the sale, the insider now owns 38,993 shares of the company’s stock, valued at $3,879,803.50. This represents a 39.07% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 109,132 shares of company stock worth $11,139,521 in the last quarter. 3.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Merit Medical Systems

Several large investors have recently bought and sold shares of MMSI. Barclays PLC increased its position in Merit Medical Systems by 305.4% during the third quarter. Barclays PLC now owns 112,727 shares of the medical instruments supplier’s stock worth $11,142,000 after buying an additional 84,923 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of Merit Medical Systems by 79.7% in the 4th quarter. Assenagon Asset Management S.A. now owns 166,927 shares of the medical instruments supplier’s stock valued at $16,145,000 after acquiring an additional 74,019 shares during the period. Park Avenue Securities LLC raised its position in Merit Medical Systems by 20.6% in the 4th quarter. Park Avenue Securities LLC now owns 4,812 shares of the medical instruments supplier’s stock valued at $465,000 after purchasing an additional 821 shares during the last quarter. Redhawk Wealth Advisors Inc. purchased a new stake in Merit Medical Systems in the 4th quarter valued at $800,000. Finally, Ballentine Partners LLC acquired a new stake in Merit Medical Systems during the 4th quarter worth $200,000. Institutional investors and hedge funds own 99.66% of the company’s stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.